Finally, the use of injectable GLP-1R agonist or GIP/GLP-1R–based medications is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or patients with type 2 multiple endocrine neoplasia syndrome [2]. The gene discussed is GIP; the disease is medullary thyroid gland carcinoma.